Zydus Cadila ties up with Italy’s SIFI to market innovative range of IOLs, surgical products in IndiaMay 6, 2019
India’s leading pharma company Zydus Cadila has tied up with Italian ophthalmic company, SIFI to market innovative IOLs (Intraocular lenses) and surgical products. These products are developed in Italy and licensed in India by SIFI.
“SIFI’s innovative intraocular lenses (IOLs) have been approved by the India’s Central Drugs Standards Control Organisation(CDSCO) and the Medical Device and Diagnostic Division of the Ministry of Health & Family Welfare,” said the Indian drug maker, which is listed on BSE as Cadila Healthcare Ltd, in a regulatory filing.
These surgical devices, according to a media statement from Zydus, represent the most advanced solution for cataract refractive surgery and the correction of astigmatism, a condition where the cornea is irregularly shaped, and presbyopia, the natural loss of near focusing ability that occurs with age.
Refractive cataract is now-a-days at the frontier of cataract surgery as it combines clouded lens removal to the simultaneous correction of refractive errors such as myopia, hypermetropia, astigmatism and presbyopia, in order to free the patient from wearing glasses following the surgery.
The highly advanced IOLs for this purpose are the EDOF (Extended Depth of Focus) lenses that present an optical plate with a continuous series of focuses, able to ensure a continuum correction from far to near in case of presbyopia and in case of astigmatism to provide compensation of the corneal abnormal curvature.
Zydus and SIFI look forward to bringing such innovations to India and to the entire South Asia region in order to empower surgeons with an advanced technology and consequently better the quality of vision and life of patients, the company statement added.
Zydus, which is currently present in several global markets, sells a broad range of therapeutical as well as preventive care products. The company that discovers, develops, manufactures and markets healthcare products, has now set a goal to become an actively research-based pharmaceutical company by 2020. While, SIFI, founded in 1935 and currently backed by private equity company–21 Invest, is a leading player in the Italian ophthalmic industry and it develops, manufactures and sells pharmaceutical treatments, diagnostic instruments and surgical equipment for eyecare, covering the vast majority of ocular pathologies.